


Data Sheet

Product Name:	BRD 4354
Cat. No.:	CS-0062885
CAS No.:	315698-07-8
Molecular Formula:	C ₂₁ H ₂₃ ClN ₄ O
Molecular Weight:	382.89
Target:	HDAC
Pathway:	Cell Cycle/DNA Damage; Epigenetics
Solubility:	DMSO : 12.5 mg/mL (32.65 mM; Need ultrasonic)



BIOLOGICAL ACTIVITY:

BRD 4354 is a moderately potent inhibitor of **HDAC5** and **HDAC9**, with **IC₅₀s** of 0.85 and 1.88 μ M, respectively. IC₅₀ & Target: IC₅₀: 0.85 μ M (HDAC5), 1.88 μ M (HDAC9)^[1]. **In Vitro**: BRD 4354 is a moderately potent inhibitor of HDAC5 and HDAC9, with BRD4354 having half-maximum inhibitory concentrations (IC₅₀) of 0.85 μ M and 1.88 μ M, respectively. BRD 4354 also inhibits HDACs 4, 6, 7, and 8 at higher concentrations (3.88-13.8 μ M) but demonstrates less of an inhibitory effect on other class I HDACs 1, 2, and 3 (IC₅₀ >40 μ M) ^[1].

PROTOCOL (Extracted from published papers and Only for reference)

Cell Assay: ^[1]A549 adenocarcinoma cells were treated with **BRD 4354** for 24 h at **10 μ M**, and the top 50 upregulated and top 50 down regulated genes are compared to other compound treatments involving drugs, bioactive compounds with established MoA, and novel synthetic compounds^[1].

References:

[1]. Boskovic ZV, ET AL. Inhibition of Zinc-Dependent Histone Deacetylases with a Chemically Triggered Electrophile. ACS Chem Biol. 2016 Jul 15;11(7):1844-51.

CAIndexNames:

8-Quinololinol, 5-chloro-7-[(4-ethyl-1-piperazinyl)-3-pyridinylmethyl]-

SMILES:

OC1=CC=CC=C2C(=CC=C1C(=CC=C2)C(Cl)C=C1C(N3CCN(CC)CC3)C4=CC=CN=C4

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 610-426-3128

Fax: 888-484-5008

E-mail: sales@ChemScene.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA